NCT Number: NCT03553381
Oxidative Stress, Inflammation, and Lipoprotein in Metabolic Syndrome
Obesity is associated with general low grade inflammation and, consequently, of oxidative stress that affects properties and functionality of lipoproteins. Metabolic syndrome exacerbate low grade inflammation. The intentional weight loss of at least 5% of the initial weight can modulate the pro-inflammatory state and reduce the oxidative stress related to the metabolic syndrome, thus diminishing the cardiovascular risk.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–55 year
Sex eligibility
All sexes
Study type
Observational
Primary location
ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milan, Italy
About this study
Metabolic syndrome is a clustering of risk factors for the development of cardiovascular disease and type 2 diabetes mellitus. Patients with metabolic syndrome have an increased general low grade inflammation and, consequently, of oxidative stress that affects properties and functions of lipoproteins (Dandona et al 2005). Intentional weight loss can improve or prevent many of the metabolic syndrome-related risk factors and these benefits are often found after weight loss of at least 5% of initial weigh.
Aim: i) to investigate the structure and functionality of plasma lipoproteins, oxidative stress and the inflammatory condition in subjects with BMI between 25kg/mq and 35 kg/mq and with or without metabolic syndrome; and ii) to test the effects of weight loss of at least 5% of initial weigh promoted by an hypo-caloric balanced diet on these parameters.
Methods: Eighty overweight and moderately obese subjects (BMI: 25 - 35 kg/m2) with or without metabolic syndrome were recruited for the study. Fasting blood samples were taken and analyzed for routine laboratory analysis, lipoprotein isolation and analysis, and oxidative stress and inflammation markers measurements. The subjects received an hypo-caloric balanced diet. Fasting blood samples were taken from subjects who had lost at least 5% of their initial weight at the end of the intervention period and analyzed for same markers determined at baseline.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
- Inclusion Criteria.
1.a Group "Obese with MS":
- BMI between 25 e 35 Kg/m2
- presence at least three of the following:1) waist circumference >102 cm for males or > 88 cm for females; 2) triglycerides: ≥ 150 mg/dL;3) HDL-cholesterol < 40 mg/dL in males or < 50 mg/dL in females; 4) hypertension (systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 85 mm Hg or antihypertensive intake); 5) glycemia: ≥ 110 mg/dL
- Alcohol consumption < 25 g/die
- No smoking or smoking less that 5 cigarettes/die
- No use of antioxidant based supplements
- Absence of hormonal treatments
- Informed consent signature
1.b Group "Obese without MS":
- BMI between 25 e 35 Kg/m2
- Alcohol consumption < 25 g/die
- No smoking or smoking less that 5 cigarettes/die
- No use of antioxidant based supplements
- Absence of hormonal treatments
- Informed consent signature
- Exclusion Criteria
- Presence of major disease
- Receiving hypoglycemic treatment
- Receiving treatments that alter lipoprotein metabolism
- Receiving hormonal treatments
- Use of antioxidant supplement
- Alcohol consumption > 25 g/die
- Smoking > 5 cigarettes/die.
- For women:pregnancy
Treatment and study plan
Primary outcomes
-
Lipoprotein and plasma oxidizability
Time frame: six months
kinetics of 2,2'-diazobis-(2-amidinopropane)-dihydrochloride (AAPH)- induced peroxidation of plasma, LDL or HDL labeled with fluorescent probes. The length of the lag phase (lag-time) and the velocity of the reaction in the propagation phase (slope) of peroxidation kinetic curves are used as indices of sample oxidizability
-
Oxygen Reactive Species (ROS)
Time frame: six months
plasma levels of ROS (mg/dL)
-
Inflammatory markers
Time frame: six months
Plasma levels of cytokines (pg/ml);
Secondary outcomes
-
Lipoprotein chemical composition
Time frame: six months
Levels of proteins (mg/dL), triacylglycerol (mg/dL), free and esterified cholesterol (mg/dL) and phospholipids (mg/dL) of very low density lipoprotein (VLDL), LDL and HDL.
-
Cholesteryl ester transfer protein (CETP)
Time frame: six months
Plasma levels of CETP (mg/dL)
Sponsors and collaborators
Lead sponsor
roberta cazzola
Other
Collaborators
- Istituti Clinici di Perfezionamento di Milano
- Luigi Sacco University Hospital
Registry information
Official study title
Oxidative Stress, Inflammation, and Lipoprotein Chemical Composition in Obesity and Metabolic Syndrome: Effects of Diet-induced Weigh Loss
Important dates
- Study start
- 2010
- Primary completion
- 2012
- Study completion
- 2018
- First posted
- Jun 12, 2018
- Registry last updated
- Jun 12, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Breath Mass Spectrometry in Metabolic Syndrome and Metabolically Healthy Obesity
NCT07330297
Body Weight, Glucose Metabolism Disorders
Moscow, Russia
View Trial DetailsImpact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes
NCT07095426
Body Weight, Glucose Metabolism Disorders
Muncie, Indiana, United States
View Trial DetailsThe Influence of Time-Restricted Eating in Patients With Metabolic Syndrome
NCT04057339
Behavior, Fasting
La Jolla, California, United States
View Trial DetailsModified Huanglian Wendan Decoction for Metabolic Syndrome
NCT07702669
Glucose Metabolism Disorders, Hyperinsulinism
Harbin, Heilongjiang, China
View Trial Details